Press "esc" to clear
Go to Advanced Search

Showing results

110 of 283

Article ID: 706333

New Leukemia Drug is More Effective and Easier to Use

Loyola University Health System

A landmark study has found that a newer targeted drug is significantly more effective than standard therapy for treating elderly patients with chronic lymphocytic leukemia (CLL). The drug, ibrutinib, attacks cancer cells without damaging normal cells, thus causing fewer side effects.

Released:
10-Jan-2019 7:05 PM EST

Article ID: 706061

Opioids Fueled a Doubling of Suicides and Overdoses in the U.S.

Michigan Medicine - University of Michigan

Suicides and drug overdoses kill American adults at twice the rate today as they did just 17 years ago, and opioids are a key contributor to that rise, according to a new review and analysis. Reversing this deadly double trend will take investment in programs that have been proven to prevent and treat opioid addiction, the researchers say.

Released:
7-Jan-2019 9:50 AM EST
  • Embargo expired:
    26-Dec-2018 5:00 PM EST

Article ID: 705798

For Patients with Kidney Disease, Genetic Testing May Soon Be Routine

Columbia University Irving Medical Center

DNA sequencing can be used to identify the underlying genetic cause of many rare types of chronic kidney disease, leading to better treatment, finds a new study from Columbia University.

Released:
21-Dec-2018 10:05 AM EST
  • Embargo expired:
    19-Dec-2018 5:00 PM EST

Article ID: 705491

Targeted Treatment Slows Progression of Rare Connective Tissue Tumor

Columbia University Irving Medical Center

About 80 percent of patients with desmoid tumors had no progression of their tumors over a two-year period while taking a drug called sorafenib during a phase 3 clinical trial.

Released:
14-Dec-2018 11:05 AM EST
  • Embargo expired:
    19-Dec-2018 5:00 PM EST

Article ID: 705505

How Children & Teens Die in America: Study Reveals the Widespread & Persistent Role of Firearms

Michigan Medicine - University of Michigan

America lost 20,360 children and teens in 2016 -- 60 percent of them to preventable injuries, a new study shows. But while death rates from the top cause – motor vehicle crashes – have declined steadily since 1999, rates from the second-leading cause - firearms - have gone up. It’s the first time all causes of child and adolescent death have been tallied by both mechanism and intent.

Released:
14-Dec-2018 1:05 PM EST
Aedes_aegypti_during_blood_meal646x363.jpg
  • Embargo expired:
    12-Dec-2018 5:00 PM EST

Article ID: 705020

15 percent of babies exposed to Zika before birth had severe abnormalities in first 18 months of life

University of California, Los Angeles (UCLA), Health Sciences

By age 12 to 18 months, 6.25% of children exposed to Zika during their mothers’ pregnancies had eye abnormalities, 12.2% had hearing problems, and 11.7% had severe delays in language, motor skills and/or cognitive function. In all, 14.5% had at least one of the three abnormalities.

Released:
5-Dec-2018 8:05 PM EST
  • Embargo expired:
    1-Dec-2018 12:00 PM EST

Article ID: 704664

Global Trial Shows CAR T Therapy Can Lead to Durable Remissions in Non-Hodgkin’s Lymphoma

Perelman School of Medicine at the University of Pennsylvania

In an update to a global clinical trial stretching from Philadelphia to four continents, the chimeric antigen receptor (CAR) T cell therapy Kymriah® (tisagenlecleucel, formerly CTL019) led to long-lasting remissions in patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL).

Released:
30-Nov-2018 8:30 AM EST
DSC06541.JPG
  • Embargo expired:
    1-Dec-2018 12:00 PM EST

Article ID: 704734

CAR-T cell update: therapy improves outcomes for patients with B-cell lymphoma

University of Chicago Medical Center

An international phase-2 trial of a CAR-T cell therapy—to be published on-line Dec. 1 in the New England Journal of Medicine (and presented at the ASH annual meeting in San Diego)—found that 52% of patients responded favorably to the therapy; 40% had a complete response and 12% had a partial response. One year later, 65% of those patients were relapse-free, including 79% of complete responders. The median progression-free survival “has not been reached.”

Released:
30-Nov-2018 4:00 PM EST
RussellWare_CintiChildrens.jpg
  • Embargo expired:
    1-Dec-2018 10:30 AM EST

Article ID: 704568

Sickle Cell Anemia Treatment Safely Lowers Disease Burden in African Children

Cincinnati Children's Hospital Medical Center

A daily hydroxyurea pill may bring relief for children living with the painful and deadly blood disease sickle cell anemia (SCA) in resource-challenged sub-Saharan Africa, where the disease is prevalent and health care is suboptimal. This is what a multinational clinical trial called REACH discovered when it tested daily hydroxyurea treatment in 606 children between the ages of 1 and 10 years old. Study data are published in the New England Journal of Medicine.

Released:
29-Nov-2018 1:00 PM EST
  • Embargo expired:
    28-Nov-2018 5:00 PM EST

Article ID: 704412

Children Who Start School a Year Early More Likely to Be Diagnosed with ADHD, Study Shows

Harvard Medical School

Children who enter elementary school younger than their peers are more likely to be diagnosed with ADHD. Children born in August in states with a Sept. 1 cutoff birth date for school enrollment have a 30 percent higher risk for ADHD diagnosis than peers born in September, which may reflect over-diagnosis.

Released:
26-Nov-2018 3:35 PM EST

Showing results

110 of 283

Chat now!